These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 16712459)

  • 1. Vitamin D receptor is a novel drug target for ovarian cancer treatment.
    Zhang X; Nicosia SV; Bai W
    Curr Cancer Drug Targets; 2006 May; 6(3):229-44. PubMed ID: 16712459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Growth suppression of ovarian cancer xenografts in nude mice by vitamin D analogue EB1089.
    Zhang X; Jiang F; Li P; Li C; Ma Q; Nicosia SV; Bai W
    Clin Cancer Res; 2005 Jan; 11(1):323-8. PubMed ID: 15671562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vitamin D Analogs Regulate the Vitamin D System and Cell Viability in Ovarian Cancer Cells.
    Piatek K; Kutner A; Cacsire Castillo-Tong D; Manhardt T; Kupper N; Nowak U; Chodyński M; Marcinkowska E; Kallay E; Schepelmann M
    Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The coupling of epidermal growth factor receptor down regulation by 1alpha,25-dihydroxyvitamin D3 to the hormone-induced cell cycle arrest at the G1-S checkpoint in ovarian cancer cells.
    Shen Z; Zhang X; Tang J; Kasiappan R; Jinwal U; Li P; Hann S; Nicosia SV; Wu J; Zhang X; Bai W
    Mol Cell Endocrinol; 2011 May; 338(1-2):58-67. PubMed ID: 21458521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vitamin D receptor-dependent inhibition of mammary tumor growth by EB1089 and ultraviolet radiation in vivo.
    Valrance ME; Brunet AH; Welsh J
    Endocrinology; 2007 Oct; 148(10):4887-94. PubMed ID: 17628009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 1α,25‑Dihydroxyvitamin D3 restrains stem cell‑like properties of ovarian cancer cells by enhancing vitamin D receptor and suppressing CD44.
    Ji M; Liu L; Hou Y; Li B
    Oncol Rep; 2019 Jun; 41(6):3393-3403. PubMed ID: 31002352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vitamin D analog EB1089 inhibits aromatase expression by dissociation of comodulator WSTF from the CYP19A1 promoter-a new regulatory pathway for aromatase.
    Lundqvist J; Hansen SK; Lykkesfeldt AE
    Biochim Biophys Acta; 2013 Jan; 1833(1):40-7. PubMed ID: 23085504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of mammary tumor cell lines from wild type and vitamin D3 receptor knockout mice.
    Zinser GM; McEleney K; Welsh J
    Mol Cell Endocrinol; 2003 Feb; 200(1-2):67-80. PubMed ID: 12644300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suppression of epithelial ovarian cancer invasion into the omentum by 1α,25-dihydroxyvitamin D3 and its receptor.
    Lungchukiet P; Sun Y; Kasiappan R; Quarni W; Nicosia SV; Zhang X; Bai W
    J Steroid Biochem Mol Biol; 2015 Apr; 148():138-47. PubMed ID: 25448740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. G2/M arrest by 1,25-dihydroxyvitamin D3 in ovarian cancer cells mediated through the induction of GADD45 via an exonic enhancer.
    Jiang F; Li P; Fornace AJ; Nicosia SV; Bai W
    J Biol Chem; 2003 Nov; 278(48):48030-40. PubMed ID: 14506229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequential versus combined treatment of human breast cancer cells with antiestrogens and the vitamin D analogue EB1089 and evaluation of predictive markers for vitamin D treatment.
    Christensen GL; Jepsen JS; Fog CK; Christensen IJ; Lykkesfeldt AE
    Breast Cancer Res Treat; 2004 May; 85(1):53-63. PubMed ID: 15039597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phytoestrogen regulation of a Vitamin D3 receptor promoter and 1,25-dihydroxyvitamin D3 actions in human breast cancer cells.
    Wietzke JA; Welsh J
    J Steroid Biochem Mol Biol; 2003 Feb; 84(2-3):149-57. PubMed ID: 12710998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apoptotic regression of MCF-7 xenografts in nude mice treated with the vitamin D3 analog, EB1089.
    VanWeelden K; Flanagan L; Binderup L; Tenniswood M; Welsh J
    Endocrinology; 1998 Apr; 139(4):2102-10. PubMed ID: 9528999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of Vitamin D compounds to modulate estrogen receptor negative breast cancer growth and invasion.
    Flanagan L; Packman K; Juba B; O'Neill S; Tenniswood M; Welsh J
    J Steroid Biochem Mol Biol; 2003 Feb; 84(2-3):181-92. PubMed ID: 12711002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of vitamin D analogs as therapeutic agents for prostate cancer.
    Chen TC; Holick MF; Lokeshwar BL; Burnstein KL; Schwartz GG
    Recent Results Cancer Res; 2003; 164():273-88. PubMed ID: 12899529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apoptosis is induced by the active metabolite of vitamin D3 and its analogue EB1089 in colorectal adenoma and carcinoma cells: possible implications for prevention and therapy.
    Díaz GD; Paraskeva C; Thomas MG; Binderup L; Hague A
    Cancer Res; 2000 Apr; 60(8):2304-12. PubMed ID: 10786699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EB1089, a vitamin D receptor agonist, reduces proliferation and decreases tumor growth rate in a mouse model of hormone-induced mammary cancer.
    Milliken EL; Zhang X; Flask C; Duerk JL; MacDonald PN; Keri RA
    Cancer Lett; 2005 Nov; 229(2):205-15. PubMed ID: 16115727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of preneoplastic mammary lesion development by a novel vitamin D analogue, 1alpha-hydroxyvitamin D5.
    Mehta RG; Moriarty RM; Mehta RR; Penmasta R; Lazzaro G; Constantinou A; Guo L
    J Natl Cancer Inst; 1997 Feb; 89(3):212-8. PubMed ID: 9017001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor effects of two less-calcemic vitamin D analogs (Paricalcitol and QW-1624F2-2) in squamous cell carcinoma cells.
    Alagbala AA; Johnson CS; Trump DL; Posner GH; Foster BA
    Oncology; 2006; 70(6):483-92. PubMed ID: 17237623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanistic studies to evaluate the enhanced antiproliferation of human keratinocytes by 1alpha,25-dihydroxyvitamin D(3)-3-bromoacetate, a covalent modifier of vitamin D receptor, compared to 1alpha,25-dihydroxyvitamin D(3).
    Chen ML; Ray S; Swamy N; Holick MF; Ray R
    Arch Biochem Biophys; 1999 Oct; 370(1):34-44. PubMed ID: 10496974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.